On the other hand, it is possible that these anti-adhesive therapies, such as anti-αv integrins, which bind to extracellular matrix proteins as fibronectin, tenascin, or vitronectin and are expressed by CD4 and CD8 T cells (e.g., αvβ3), affect the quality of the immune synapses established in the tumor microenvironment, thereby preventing immune protection. Here, CD8A is linked to neoplasm.